COMMENTARY: Review: Long-term anticoagulation reduces recurrent venous thromboembolism

Witt, Daniel M.; Siragusa, Sergio
March 2006
ACP Journal Club;Mar/Apr2006, Vol. 144 Issue 2, p33
Academic Journal
The article focuses on a study which reveals that for patients with venous thromboembolism (VTE), 4 to 6 weeks of anticoagulant therapy is inferior to longer treatment and that risk for recurrent VTE during ongoing anticoagulation is negligible. Indefinite anticoagulation is warranted in patients with active cancer. In patients with unprovoked VTE or those who are heterozygous carriers of the factor V or prothrombin gene mutations, the duration of treatment is controversial.


Related Articles

  • Understanding Bleeding Risk after Anticoagulation.  // PLoS Medicine;Oct2005, Vol. 2 Issue 10, p931 

    Discusses research being done on anticoagulants. Reference to a study by Pieter Reitsma et al in a 2005 issue of "PLoS Medicine"; Number of patients receiving anticoagulants included in the study; Risk of bleeding among phenprocoumon and acenocoumarol users; Potential factor that influences the...

  • Anticoagulants. Nicholls, Charlotte; Sani, Mojgan // Nursing Older People;Oct2004, Vol. 16 Issue 7, p35 

    This article reports that in a continuing series of drug and therapeutics updates, Charlotte Nicholls and Mojgan Sani consider the enduring role of anticoagulants in the treatment of thromboembolic diseases. Anticoagulants were discovered in 1924 when a new haemorrhagic disorder was discovered...

  • Risk Factors and Long-term Follow-up of Patients with the Immune Type of Heparin-Induced Thrombocytopenia. Lindhoff-Last, Edelgard; Wenning, Britta; Stein, Martina; Gerdsen, Frank; Bauersachs, Rupert; Wagner, Roland // Clinical & Applied Thrombosis/Hemostasis;Oct2002, Vol. 8 Issue 4, p347 

    Dispositional risk factors for developing the immune-type of heparin-induced thrombocytopenia (HIT) are yet unclear. This article presents a long-term follow-up of patients with HIT to define possible risk factors that may increase the risk of HIT. The clinical course of acute HIT was analyzed...

  • Snake Venom Prothrombin Activators Similar to Blood Coagulation Factor Xa. Joseph, Jeremiah S.; Kini, R. Manjunatha // Current Drug Targets - Cardiovascular & Haematological Disorders;Dec2004, Vol. 4 Issue 4, p397 

    Activation of prothrombin to mature thrombin in vivo occurs by the proteolytic action of the prothrombinase complex consisting of serine proteinase factor Xa, and cofactors that include factor Va, Ca2+ ions and phospholipids. Several exogenous prothrombin activators are found in snake venom....

  • CLINICAL EXPERIENCE WITH COUMADIN SODIUM, A NEW ANTICOAGULANT DRUG. Pollock, Byron E. // Angiology;Dec1955, Vol. 6 Issue 6, p506 

    Cites a study in which Coumadin sodium has been used as the hypoprothrombinemia agent in 100 clinical cases requiring anticoagulant therapy. Administration of the initial dose of Coumadin sodium intravenously while maintenance dosage was given orally; Effect of Coumadin sodium therapy on...

  • Validity of International Normalized Ratio in Expressing Prothrombin Times in Anticoagulated and Nonanticoagulated Patients. Alshameeri, Rasheed; Mammen, Eberhard F.; Paisley, Christa; Perry, Christine // Clinical & Applied Thrombosis/Hemostasis;Winter1996, Vol. 2 Issue 1, p25 

    We investigated the effect of four thromboplastins with different International Sensitivity Index (ISI) values on prothrombin times (PTs), expressed as International Normalized Ratios (INRs), of 30 normal plasmas, 30 patients on stable oral anticoagulant (OA) therapy, and 30 patients with...

  • Lupus anticoagulants in two children-bleeding due to nonphospholipid-dependent antiprothrombin antibodies. Knobe, Karin; Tedgård, Ulf; Ek, Torben; Sandström, Per-Erik; Hillarp, Andreas // European Journal of Pediatrics;Sep2012, Vol. 171 Issue 9, p1383 

    We describe two children with significant bleeding: one with multiple ecchymoses and the other with scrotal bleeding. In both patients, the activated partial thromboplastin time (APTT) was prolonged, with positivity for lupus anticoagulants (LA). However, the Owren prothrombin time (PT), usually...

  • Look at evidence on anticoagulants. Lethaby, Anne // New Zealand Doctor;10/20/2004, p30 

    Focuses on the recommended process in prescribing anticoagulant treatment for patients with paroxysmal atrial fibrillation. Appropriate application of risk stratification; Calculation of the patient's risk score for stroke or death; Method in expressing the risks and benefits of alternative...

  • Oral anticoagulant and antiplatelet drugs used in prevention of cardiovascular events in elderly people in Poland. Labuz-Roszak, Beata; Pierzchala, Krystyna; Skrzypek, Michal; Swiech, Marta; Machowska-Majchrzak, Agnieszka // BMC Cardiovascular Disorders;2012, Vol. 12 Issue 1, p98 

    Background: In Poland, the prevalence of cardiovascular diseases is increasing. This might be associated with the constantly growing proportion of elderly people and inappropriate cardiovascular prevention. This study aimed to evaluate the frequency of use of oral antiplatelet (OAP) and oral...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics